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Abstract
Background: Despite the potential to produce antibodies that can neutralize different virus (heterotypic
neutralization), there is no knowledge of why vaccination against influenza induces protection predominantly
against the utilized viral strains (homotypic response). Identification of structural patterns of the B cell
repertoire associated to heterotypic neutralization may contribute to identify relevant epitopes for a universal
vaccine against influenza.
Methods: Blood samples were collected from volunteers immunized with 2008/2009 trivalent inactivated
vaccine (TIV), pandemic H1N1 (pdmH1N1) monovalent inactivated vaccine (MIV) and the 2014/2015 TIV.
Neutralization was assessed by hemagglutination and microneutralization test. IgG VH amplicons derived from
peripheral blood RNA from pre-immune and 7 days post vaccination were subjected to 454-Roche sequencing.
Full reconstruction of the sampled repertoires was done with ImmunediveRsity.
Results: The TIV induced a predominantly homotypic neutralizing serologic response, while the 09 MIV induced a
heterotypic neutralizing seroconversion in 17 % of the individuals. Both the 08/09 and the 14/15 TIV were associated
with a reduction in clonotypic diversity, whereas 09 MIV was the opposite. Moreover, TIV and MIV induced distinctive
patterns of IGHV segment use that are consistent with B cell selection by conserved antigenic determinants shared by
the pre-pandemic and the pandemic strains. However, low somatic hypermutation rates in IgG after 09 MIV
immunization, but not after 08/09 and 14/15 TIV immunization were observed. Furthermore, no evidence of the
original antigenic sin was found in the same individuals after vaccination with the three vaccines.
Conclusions: Immunization with a new influenza virus strain (2009 pdmH1N1) induced unique effects in the
peripheral B cell repertoire clonal structure, a stereotyped response involving distinctive IGHV segment use and
low somatic hypermutation levels. These parameters were contrastingly different to those observed in response
to pre-pandemic and post-pandemic vaccination, and may be the result of clonal selection of common
antigenic determinants, as well as germinal center-independent responses that wane as the pandemic strain
becomes seasonal. Our findings may contribute in the understanding of the structural and cellular basis
required to develop a universal influenza vaccine.
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Background
Influenza viruses cause seasonal outbreaks and eventu-
ally pandemics with a high cost in morbidity and mortal-
ity at a global level [1, 2]. Yearly influenza outbreaks are
ascribed to the significant mutation ability of the virus.
Structural variability of the viral hemagglutinin (HA)
(antigen drift) [3], the main viral antigen responsible for
interaction with the sialic acid on the host’s cells surface,
allows viral escape from neutralization by antibodies
induced by previous exposures to a particular viral
strain. In contrast, pandemics are caused by the intro-
duction of new viruses that result from genes re-
assortment (antigen shift), for which there is no pre-
existing immunity (mainly against the new HA); leading
to rapid global spread [3]. Despite the enormous vari-
ability of influenza viruses, the induction of specific neu-
tralizing antibodies through vaccination continues to be
an effective intervention for seasonal influenza preven-
tion, with the constant challenge of renewing the vaccine
strain formulation every year in order to counteract the
antigen drift, and the limitation of being ineffective in
pandemic prevention [4, 5].
Eighteen HA subtypes, with a protein sequence iden-
tity between 40 % and 60 %, divided into two phylogen-
etic groups, have been described [6]. On the virion
surface, HA is trimeric, and each monomer contains a
globular domain with a high mutation frequency and a
stem with a more conserved structure [3]. Both natural
infection and vaccination induce the production of neu-
tralizing antibodies mainly directed against the globular
domain, known as homotypic neutralizing antibodies,
which are incapable of neutralizing other virus subtypes
or certain drift variants of the original subtype. However,
the presence of antibodies with heterotypic neutralizing
capacity – that is, antibodies with the ability to
neutralize several strains and subtypes of the virus – has
been described in a murine model [7], and more recently
in humans [8–10]. Most of these antibodies are directed
towards the HA stem, whose sequence is more con-
served among virus subtypes and is essential for endoso-
mal virion-host cell membrane fusion [3]. As for why
heterotypic neutralizing antibodies do not prevail over
homotypic neutralizing antibodies, and why they are not
produced in all individuals in relevant amounts to pro-
vide protection remain open questions. The answer to
these questions would open up the possibility of devel-
oping a universal vaccine that may prevent a significant
number of virus subtypes, including new variants with
pandemic potential [11–14].
Lymphocytes represent a highly diverse population at
a cellular and molecular level, which is dynamically
modified by selective processes resulting from the indi-
viduals’ interaction with their environment [15]. The
ability to produce highly specific antibodies against
virtually any antigen (adaptive capacity) depends upon
the generation of a large diversity of antigen receptors
exposed on the surface of B cells (B cell receptor or
BCR). Each lymphocyte expresses a single antigen recep-
tor [16]. The diversity of BCRs is generated through the
somatic recombination process or V(D)J recombination,
which occurs independently of the antigen. Considering
the multiplicity of V, D, and J segments encoded in the
germ-line, their ability to combine and the junction re-
pair processes (junction diversity), the potential diversity
of the B-lymphocyte repertoire has been estimated to be
1 × 1011 [17].
The great diversity of the B-lymphocyte repertoire im-
plies that their interaction with the antigen induces a
clonal expansion process (positive selection) resulting in
the amplification of the number of clones and the pro-
duction of specific antibodies against the pathogen or
the vaccine in biologically relevant quantities. During
T-dependent clonal selection, antigen-specific B cell
clones undergo somatic hypermutation (SHM) in the
V region, allowing the selection and differentiation of
high affinity memory B cells, which are the biological
basis of vaccination. Therefore, in order to develop a
universal influenza vaccine [18], it is essential to
understand how viral diversity shapes B cell clonal se-
lection and competition to favor or disfavor broadly
neutralizing B cell clone selection.
Within the context of the recent 2009 influenza pan-
demic, it was surprising that the virus belonged to the
A(H1N1) subtype due to the expectation of a predomin-
ance of homotypic neutralizing immunity at population
level resulting from natural infection and/or vaccination
with pre-pandemic H1N1 strains [19, 20]. However, crys-
tallographic studies of the HA of the new 2009 pdmH1N1
virus revealed its structural and antigenic similarity with
the H1N1 virus of the 1918 pandemic, which ceased to
circulate among human populations since the 1950s [21].
In spite of having HA of the H1 subtype, the H1
globular domain of the 2009 pdmH1N1 and seasonal
pre-pandemic H1N1 viruses have diverged significantly
through drift, and therefore were considerably structur-
ally different [21, 22]. Studies in natural infection and
vaccination with the 2009 pdmH1N1 strain revealed a
predominant heterotypic responses directed to the HA
stem, suggesting B cell selection of subdominant clones
against conserved epitopes of the HA stem [23, 24].
Thus, the 2009 pandemic was a historic opportunity to
longitudinally analyze the immune response in humans
against a new viral strain with a high divergence in the
H1 globular domain, but conserved stem structure.
In this work, we analyze the induction of homotypic
and heterotypic antibody responses to vaccination with
pre-pandemic 2008/2009 trivalent Influenza vaccine
(08/09 TIV), followed by the 2009 monovalent influenza
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vaccine (09 MIV). Additionally, the peripheral blood
IgG VH B cell repertoire was characterized in six indi-
viduals (born after 1950), 7 days after immunization
with the 08/09 TIV, when antigen-specific plasmablast
mobilization takes place [23, 25]. This repertoire was
compared to that induced by a subsequent immunization
with the monovalent inactivated vaccine against 09 MIV,
and a third vaccination trial with the 2014/2015 TIV,
which includes the 2009 pdmH1N1 HA antigen. The
comparative analysis of the repertoires in the same indi-
viduals allowed the identification of common IGHV usage
and signatures and somatic hypermutation pattern associ-
ated with seasonal vaccines (08/09 TIV and 2014/15 TIV)
in contrast with 09 MIV.
Methods
Ethics statement
This study was conducted according to the principles
expressed in the Declaration of Helsinki. The study was
approved by the Research, Ethics, and Biosafety
Committees of the Instituto Nacional de Salud Pública
(INSP) (CI: 971), and Instituto de Diagnóstico y Referencia
Epidemiológicos (InDRE). Written informed consent of all
participants was obtained.
Vaccination of volunteers and sample collection
During the initial phases of the 2009 pdmH1N1 influ-
enza pandemic, six clinically healthy participants aged
over 28 and under 41 years working at INSP manifested
their intention to receive the 2008/09 trivalent inactivated
influenza vaccine (TIV) (FLUARIX, GSK. A/Brisbane/59/
2007(H1N1), A/Brisbane/10/2007(H3N2), B/Florida/4/
2006). These individuals were invited (after signing an
informed consent document) to donate four peripheral
blood samples: one before the vaccination (day 0), and the
others on days 7, 14, and 30 after the vaccination.
Twenty-four months later, five of these individuals and 18
individuals who had not been vaccinated in the 2009 trial
and whose vaccination history and exposure to the influ-
enza virus was unknown, were recruited for a second trial
to receive the 2009 pdmH1N1 MIV (non-adjuvanted,
15 μg hemagglutinin (HA) of influenza A/California/07/
2009 (H1N1) v–like virus Sanofi Pasteur). They donated
peripheral blood samples before (day 0), 7, 14, and 30 after
the vaccination. Peripheral blood samples for serum
and RNA (PAXgene Blood RNA Tubes. PreAnalytiX)
were collected from each of the participants through
venipuncture, and the total RNA was extracted according
to manufacturer’s instructions. Finally, four individuals
previously vaccinated with 08/09 TIV and 2009 pdmH1N1
MIV were vaccinated with 2012/13 TIV and 2014/15
TIV (FLUARIX, GSK. A/Christchurch/16/2010 NIB-74XP
(H1N1) (an A/California/7/2009-like virus), 273 A/Texas/
50/2012 NYMC X-223A (H3N2), and B/Massachusetts/2/
2012 NYMC BX-51B), as a part of the Institutional sea-
sonal influenza vaccination program. Blood samples from
these individuals were taken as described for the previous
vaccination trials. The overall design of the experiment is
depicted in Fig. 1.
Hemagglutination inhibition assays
Hemagglutination inhibition assays (HIA) [26] were per-
formed in order to determine serum antibody titers against
the pre-pandemic 2008/2009 A(H1N1) and H3N2 and
2009 pdmH1N1 virus strains in samples of day 0 and
30 days after the vaccination with 08/09 TIV and 09 MIV.
In short, non-specific agglutinins were eliminated and ser-
ial serum dilutions were mixed with an equal amount of
PBS with 8 hemagglutinating units of each viral strain. The
dilution at which the tests were considered positive was
1:40. Seroconversion to the vaccine was defined as a four-
fold increase in the day 0/day 30 post-vaccination titers.
Plate microneutralization tests
This assay [27] makes it possible to quantify total neu-
tralizing antibodies against the influenza virus, not only
Fig. 1 Experimental design timeline of immunizations and sequencing experiments. Six individuals naïve for 2009 pdmH1N1 were vaccinated
with the 08/09 TIV and their peripheral blood IgG B cell repertoire was sequenced before vaccination (day 0) and 7 days after vaccination. Two
years later, the IgG B cell repertoire of five to six individuals previously vaccinated plus eight additional participants vaccinated with 09 MIV (of 18
participants) were sequenced (day 0 and day 7). Finally, four of the same five participants vaccinated with 08/09 TIV and 09 MIV were vaccinated
with 12/13 TIV. The same four participants were then vaccinated with 14/15 TIV and subjected to Rep-Seq (*), as in the previous trials. The overall
experiment length from the first to the last vaccination trial was 5 years, 5 months
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those directed against the HA globular domain. For this
purpose, serial serum dilutions (days 0, 7, 15, and 30)
were incubated with viral strains A(H1N1) 2008,
A(H3N2) 2008 and AH1N1pdm 2009), and the residual
virus-serum mix infectiveness for MDCK of cells was
determined using an ELISA with an anti-NP antibody.
Neutralizing titers were defined as the reciprocal of the
highest serum dilution that totally neutralized the viral
infection. The minimum dilution at which a test was
considered positive was 1:80. Seroconversion to the vac-
cine was defined as a four-fold increase in the day 0/day
30 post-vaccination titers.
Generation of VH gene libraries for massive cDNA
sequencing
Peripheral blood RNA was stored at -70 °C, and an ali-
quot was used to analyze its concentration and integrity
through capillary electrophoresis in a 2100 BioAnalyzer,
with the Agilent RNA 6000 Pico kit (Agilent). To
characterize the clonal structure of the B cell repertoire
in response to 08/09 TIV, 09 MIV, and 14/15 TIV, and
to avoid potential amplification biases [28], we used 5′
RACE-PCR [29]. cDNA was generated for the VH region
of the IgG compartment on day 0 (pre-immune) and
7 days after the vaccination, to coincide with the peak of
circulating antigen-specific plasmablasts [23, 25]. For
each VH amplicon library, 1 μg of RNA was used to
synthesize cDNA. The cDNA generated had a known
DNA sequence (adaptor) at the 3′ end, and the oligo-
nucleotide (dT) sequence at the 5′ end. cDNA was used
as template to produce amplicons containing the diversity
generated through V(D)J recombination of the heavy
chain. We substituted the TS-PCR oligonucleotide of the
Matz protocol [29] for the FpAmpTA oligonucleotide,
which is identical to TS-PCR except that it contains the
sequence of the A adaptor, which is necessary for the
massive amplicon sequencing protocol developed by 454-
Roche. The gene libraries were generated using FpAmpTA
together with the TBIgGHu oligonucleotide, which primes
amplification specifically in the segment that encodes for
exon I of IGHG (1-4) and contains adaptor B sequence
required for massive sequencing. The products of the 5′-
RACE-PCR reactions (500-600 bp) were analyzed by elec-
trophoresis in agarose gels at 1.5 % and were purified from
the gel using the MiniElute PCR purification kit (Qiagen).
The concentration and integrity of the gene libraries were
analyzed through capillary electrophoresis in the 2100
BioAnalyzer, using the High Sensitivity DNA kit (Agilent).
High throughput DNA sequencing of gene libraries
Approximately 100 ng of each of the 44 gene libraries
were analyzed for clonal amplification by emulsion PCR
using the 454-Roche GS emPCR kit, according to the
manufacturer’s instructions. The sequencing of the gene
libraries was carried out using the GS FLX Titanium
Sequencing kit XLR70, according to the manufacturer’s
instructions. This system allows the generation of se-
quences with an average length of 450 bp. In order to se-
quence at least the CDRH3 region and partially the
IGHV region, the sequencing was carried out in antisense,
that is, from the B adapter. Raw sequencing files were
submitted to NCBI-SRA: BioProject ID: PRJNA301150;
Accessions: SAMN04240435-78.
Bioinformatics analysis with the ImmunediveRsity
platform
We have developed ImmunediveRsity [30], a bioinfor-
matics analysis platform based on the R language for the
automated analysis of the structural diversity of the B-
lymphocyte repertoire. This data processing platform be-
gins with quality screening. Sequence files were screened
in order to exclude non-VH sequences (for example,
germ-line transcripts), by mapping the human genome,
reads under 200 bp and reads with an average quality
value of < Q28. After quality filtering, ImmunediveRsity
assigns IGHV and IGHJ segment use to each read using
IgBLAST (http://www.ncbi.nlm.nih.gov/igblast/). Incor-
rect assignment of the IGHD segment is very common
(approximately 50 % of the cases); therefore, the
IGHD assignment is omitted. For every different V-J
rearrangement, each read is assigned to a VH clonotype
through identification of the segment encoding for
CDRH3 using hidden Markov models [31], followed by its
recursive clustering with USEARCH [32], based on length
identity and a 97 % sequence identity. Because only the
heavy chain variable region (IGHV) was sequenced, this
method does not describe sensu stricto lineages (clonally
related IGH + IGL pairs). Henceforth, we describe IGHV
sensu lato lineages as the consensus generated through
the recursive clustering of reads with ≥99.5 % identity that
belong to the same VH clonotype, but diversified by
somatic hypermutation. ImmunediveRsity output files
for each sequenced library can be found at http://
201.131.57.23:8080/influenza-project/.
Somatic hypermutation analysis
For each lineage consensus, the numbers of non-
synonymous and synonymous mutations were obtained
with IMGT/HighVQuest [33]. Only productive lineages
were used for random sub-sampling (670 lineages per li-
brary, which corresponds to the library with the least
number of lineages). The proportion of mutations
(pM-VH) was calculated as the percentage of total of
mutations in VH region, excluding the CDRH3, divided
by its length. To avoid non-independence effects from
lineages derived from large clonotypes, SHM was also
calculated in the largest lineage per clonotype from 250
randomly sampled clonotypes.
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Analysis of the structural diversity of the B-lymphocyte
repertoire
In order to quantify the clonal and lineage diversity, rar-
efaction curves [34] were plotted with growing subsam-
ples of 1,000 reads. The Shannon-Weaver index (DSW)
(entropy) was used as a proxy to clonotype and lineage
diversity [35]. For IGHV segment use analysis, differ-
ences between the pre-immune groups and at 7 days
post-vaccination groups were statistically evaluated using
the GraphPad Prism 5.04 software. To identify the
changes induced by the corresponding vaccines, the rela-
tive frequency of unclustered reads and VH clonotypes
of the post-vaccination use of IGHV segments was sub-
tracted from the corresponding pre-immune frequency
(Δ day 7 – day 0).
Principal component analysis of diversity, IGHV use, and
mutation frequency
Comparisons among 2008/09 TIV, 09 MIV and 2014/15
TIV based on rarefaction analysis (d7/d0 ratio at 12,000
read sampling effort), Shannon entropy (DSW d7/ DSW
d0 ratio), IGHV1-69, IGHV3-7, and IGHV4-39 use (Δ
day 7 – day 0) and mutation rate at day 0 and at day 7
post vaccination for each individual were performed
with a multilevel principal component analysis (PCA)
[36]. Graphical representation of Component 1 (PC1)
versus Component 2 (PC2), selected by the criteria of
proportion of explained variance (that is, accounts for as
much of the variability in the data as possible) was done
with a biplot graph. This analysis was conducted using R
software [37] and FactoMineR library.
Clonal expansion analysis and recombinant monoclonal
antibody production
Clonal expansion using particular IGHV segments were
defined as an increase of ≥3 standard deviations (SD) in
the change of clonal frequency (Δ day 7 – day 0). The
two biggest lineages of the largest heavy chain clono-
types of clonal expansions observed in silico were se-
lected for experimental validation of anti-Influenza virus
specificity. The sequence corresponding to the VH region
flanked by EcoRI and NheI restriction sites were synthe-
sized as gene fragments (Gblocks, IDT) and cloned in
the expression vector of human antibody heavy chains
pVAJO-CHG1, plasmid coding for human IgG1, as de-
scribed [38]. The selected VH sequences were matched
with seven different variable region sequences of light
chain (VL) (See Additional file 1). The VL sequences,
synthesized also as gene fragments (Gblocks, IDT), were
cloned in the expression vector of antibody light chains
pVAJO-CLhk or pVAJO-CLhl. The sequence of the re-
combinant plasmids was verified by Sanger sequencing.
To produce monoclonal antibodies, each heavy chain-
encoding plasmid was co-transfected with each of the
light chain-encoding plasmid into HEK 293 T cell line
(Thermo) and supernatants were collected 48 h later.
Validation of anti-influenza specificity by ELISA
After transfection, IgG production in supernatants was
verified by anti-human IgG ELISA (data not shown). IgG
positive supernatants (100 μL) were then tested by
ELISA for reactivity against the 09 MIV (influenza A/
California/07/2009 (H1N1) v–like virus Sanofi Pasteur)
or 08/09 TIV (FLUARIX, GSK. A/Brisbane/59/
2007(H1N1), A/Brisbane/10/2007 (H3N2), B/Florida/
4/2006) coated-96 well plates in pH 7.4 PBS/Tween-
20 0.1 % (300 ng per well). After washing, wells were
incubated with goat anti-human IgG coupled with
HRP (1:5,000. Abcam), washed, and read at 490 nm.
Results
Vaccination with the 08/09 TIV does not induce
seroconversion against 2009 pdmH1N1
During the onset of the pandemic (May, 2009), six indi-
viduals were vaccinated with the 08/09 TIV. The pre-
immune serum of three (50 %) and two (33.3 %) individ-
uals showed positive hemagglutination inhibition assay
(HIA) for 2008 A(H1N1) and 2008 A(H3N2), respect-
ively, which is indicative of pre-exposure to seasonal vi-
ruses and is expected among the general population. All
pre-immune samples were negative for 2009 pdmH1N1
in HIA, while 5/6 (83 %) presented low but positive
titers (≥80) in the microneutralization test (MN)
(Additional file 2). Seroconversion rate as measured
by HIA for pre-pandemic H1N1 and H3N2 strains
was 16 % and 33 %, respectively. No individual showed
seroconversion against the 2009 pdmH1N1 in HIA and
MN in response to immunization with TIV (heterotypic
seroconversion) (Fig. 2a). The high seropositivity rate
to pre-pandemic viruses is consistent with previous
exposures to different influenza viruses of the studied
population. The absence of heterotypic seroconversion
(against 2009 pdmH1N1) is consistent with the pro-
motion of homotypic neutralizing responses by vac-
cination with TIV.
Vaccination with 09 MIV induced seroconversion against
2008 A(H1N1) in a subgroup of individuals
Two years after immunization with TIV, five out of the
six immunized individuals and an additional group of 18
individuals were immunized with the 09 MIV vaccine
against the 2009 pdmH1N1 virus. As in the TIV assay,
none of the 23 individuals tested positive for 2009
pdmH1N1 with HIA on day 0; however, 14 individuals
(60 %) showed low but positive titers (≥80) in MN. Sero-
positivity against 2008 A(H1N1) and 2008 A(H3N2)
measured with HIA on day 0 was 0 % and 8 %,
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respectively, whereas measured with MN was 47 % and
65 %, respectively (Additional file 2).
As a result of 09 MIV immunization, the homotypic
seroconversion rates for 2009 pdmH1N1 in HIA and
MN were 86 % and 75 %, respectively. There was no het-
erotypic seroconversion for 2008 H3N2 in both tests.
Interestingly, 4/23 individuals (17 %) showed heterotypic
seroconversion against 2008 A(H1N1) in MN, but not in
HIA (Fig. 2b). The apparent inconsistency in the results
of seroconversion between MN and HIA may be ex-
plained by the induction of a cross-neutralizing antibody
response to HA antigenic determinants outside the HA1
domain (that is, anti-stem antibodies). These results in-
dicate that in addition to the expected homotypic re-
sponse, the 09 MIV vaccine induced in some individuals
a heterotypic response, which is consistent with recent
findings that 09 MIV re-stimulated B cells that recognize
common antigenic determinants between 2008 A(H1N1)
and 2009 pdmH1N1 [23, 24, 39].
Sequencing the peripheral blood B cell repertoire
To structurally characterize and compare the B cell
clonal response to vaccination with 08/09 TIV, 09 MIV,
and 14/15 TIV, as well as to identify whether there are
repertoire signatures associated to each vaccine and to
the homotypic and heterotypic responses, we sequenced
the VH region of IgG from total RNA of peripheral blood
lymphocytes before and 7 days after vaccination in each
vaccination trial. We generated a total of 778 mbp
and 1.7 million sequencing reads, with an average of
17.6 mbp and 40,000 reads per VH amplicon library.
The average read length was 449 ± 51 bp, which is
sufficient to cover the entire VH region length. This
allowed a detailed analysis of 218,910 lineages (unique
heavy chain, see Materials and Methods), corresponding
to an average of 4,975 VH lineages per VH amplicon
library (Table 1). See Additional file 3 for detailed reper-
toire metrics.
Vaccination with TIV and 09 MIV induced different
responses in terms of the clonotypic and lineage diversity
of the IgG peripheral blood B cell repertoire
Antigen recognition in the secondary lymphoid organs
involves clonal selection and diversification by SHM,
which affects the clonal structure and diversity of the
repertoire. To quantify the peripheral B cell clonal di-
versity and its modification in response to vaccin-
ation, we used in population ecology techniques to
assess species richness and diversity. We expected
that vaccine induced mobilization of clonally related
plasmablasts displaying high levels of Ig transcription,
compared to memory B cells would manifest as a
rapidly saturating rarefaction curve. Indeed, as shown
in Fig. 3, 08/09 TIV induced a reduction of clonotype
A B
Fig. 2 Vaccination with TIV induced homotypic seroconversion (a), while 09 MIV induced heterotypic seroconversion against pre-pandemic
H1N1 (b). Homotypic and heterotypic seroconversion rates for vaccination with TIV and 09 MIV. TIV showed low seroconversion rates for vaccine
strains due to pre-exposure (high pre-vaccination titers) (n = 6). The 09 MIV vaccine had a higher homotypic seroconversion (83 % and 75 %) and
heterotypic seroconversion against 2008 H1N1 in 17 % of the immunized participants (n = 23) (arrow)
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and lineage diversity compared to the pre-immune
sample (Fig. 3a and d). Conversely, vaccination with
09 MIV was associated with an increase in clonal group
and lineage diversity post-vaccination (Fig. 3b and e).
Interestingly, immunization with 14/15 TIV showed no
differences between the pre-immune and 7 days post
immunization (Fig. 3c and f).
To confirm the results of the rarefaction analysis, we
estimated the Shannon-Weaver diversity index (DSW) on
days 0 and 7 after vaccination in each trial (08/09 TIV,
09 MIV, and 14/15 TIV). To account for differences in
the number of circulating IgG+ B cells within individuals
in the different vaccination trials, we calculated the Dsw
day 7/ Dsw day 0 ratio. The 08/09 TIV trial consistently
showed ratios <1.0 (reduction of the diversity with re-
spect to day 0) in both clonal groups and lineages
(Additional file 4, A and B), indicating a reduction of
clonal and lineage diversity. Contrastingly, the DSW
day 7/ DSW day 0 ratio in response to vaccination with 09
MIV was consistently higher than with both TIVs and
Table 1 Sequencing metrics of the analyzed VH sequences
Sequencing results Parameter Totalsa Amplicon library (Average ± SD)b
Raw output 454 reads 1,792,504 40,738 ± 27,496
Total bases (bp) 778,487,667 17,692,901 ± 12,073,169
Average length (bp) ND 483 ± 77
Quality and size filters Eliminated reads (%) 27 % 24 % ± 14
Sequences included in the analysis Analyzed with ImmunediveRsity 1,302,865 29,610 ± 18,114
Clonotypes 71,568 1,626 ± 938
Lineages 218,910 4,975 ± 3,378
aTotal parameters of five 454-Roche Titanium sequencing runs. Forty-four gene libraries were generated from 13 individuals
bEach gene library corresponds to one of six conditions: day 0 and day 7 after vaccination with TIV2008/2009, day 0 and day 7 after vaccination with 09 MIV2009,
and day 0 and day 7 after vaccination with TIV2014/2015
A B C
D E F
Fig. 3 Vaccination with 08/09 TIV induced a reduction of the clonal and lineage diversity, while 09 MIV induced an increase in the diversity.
A rarefaction analysis (a-d) was performed with progressive subsamples of 1,000 reads (axis x), plotted against the average standard error
of clonal groups (a-c) and lineages (d-f) for 08/09 TIV (a and d), 09 MIV (b, e), and 14/15 TIV (c, f) vaccination trials. The empty symbols
represent the values for day 0 (pre-immune), while the black symbols stand for those for day 7 after vaccination (two-way ANOVA. *P <0.05;
**P <0.01; ***P <0.001). Fluctuations above 7,000 reads in pre-immmune are due to insufficient sequencing depth in two individuals (see also
Additional file 3)
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above 1.0 (Additional file 4, A and B). As for the 08/09
TIV trial, the Dsw day 7/ Dsw day 0 ratio in response to a
third vaccination with 14/15 TIV was below 1.0. These re-
sults suggest that the clonal response to 08/09 and 15/15
TIV is more similar compared to 09 MIV and suggests
that vaccination with 09 MIV promotes mobilization
of a more diverse plasmablast population into periph-
eral blood.
Immunization with TIV and 09 MIV induced differential
changes in the clonal frequency of B cells using IGHV1-69,
IGHV3-7, and IGHV4-39
To characterize the B cell response to each vaccine in
terms of the BCR structural determinants involved in
recognition of common and unique antigenic determi-
nants of the different influenza virus strains, we deter-
mined the relative frequency usage of IGHV segments as
relative transcription (unclustered reads), or as their
proportional usage frequency at the clonotypic level.
Changes in the frequency usage were expressed as the
difference between post-immunization (day 7) minus
pre-immune frequencies (Δ day 7 – day 0). For the
2008/09 TIV, only IGHV1-69 and IGHV4-39 out of 47
IGHV segments analyzed, showed significant differences
at the clonotypic level in response to immunization with
either of the two vaccines (Fig. 4a) (two-way ANOVA.
P <0.0001 and P <0.001, respectively).
In most of the analyzed individuals, the IGHV1-69
clonal frequency was the opposite according to the
vaccination assay: in response to 08/09 TIV, the post-
vaccination clonal frequency was lower than pre-
vaccination levels in all individuals. Conversely, the
post-vaccination clonal frequency of IGHV1-69 was
equal or higher than the pre-immune level in response to
09 MIV (Fig. 4a and b). As for B cells using IGHV4-39, a
similar but opposite behavior was observed, since TIV
induced a clonal frequency increase, whereas 09 MIV
induced a reduction (Fig. 4a and d).
Clonal frequency of B cells using IGHV3-7 increased
significantly only in response to vaccination with 09
MIV (P <0.0001). This increase occurred due to two out-
lier individuals (i05 and i07), in which a high fraction of
clones used IGHV3-7 (from 3 % at day 0 to 49.5 % and
3.7 at day 0 to 26 %, respectively) (Fig. 4a and c), occu-
pying a large fraction of the VH transcriptome (from 2 %
at day 0 to 81 % and 1.7 % at day 0 to 57 %, respectively,
Fig. 4c). To identify if allelic differences could favor the
selection of some clonotypes, we identified that indi-
viduals i05 and i07 that showed clonal expansions in
IGHV3-7 were heterozygous for IGHV3-7*01/IGHV3-
7*03 and homozygous for IGHV3-7*01, respectively.
The rest of the individuals that did not show clonal
expansion in IGHV3-7 expressed were homozygous
for *01 (4/13), heterozygous *01/*03 (5/13) or
heterozygous for *03 (2/13). In the heterozygous indi-
vidual (i05), the expanded clones corresponded to the
*03 allele. Thus, at least for the IGHV3-7 segments,
alleles *01 and *03 do not determine a selective clonal
advantage for 09 MVI. Taken together, these results
suggest that different individuals respond similarly in
terms of IGHV1-69 and IGHV-4-39 segment use, in
which the clonal structure of the peripheral blood B
cells was modified inversely in response to both vac-
cines. Furthermore, the IGHV3-7 segment was mark-
edly expanded in two individuals only in response to
09 MIV.
Re-vaccination trial with the 2014/1015 TIV recapitulates
the 2008/2009 pre-pandemic TIV vaccination in terms of
IGHV1-69 and IGHV4-39 usage
The increased use of IGHV1-69 in response to 09 MIV
has been implicated in the predominant anti-HA2 het-
erotypic response resulting of natural infection and vac-
cination with the 2009 pdmH1N1 [23, 24, 39]. We asked
if repeated exposure after an initial challenge with 2009
pdmH1N1 would revert the pattern of IGHV use to that
observed with the 08/09 TIV. Thus, we evaluated rela-
tive IGHV use at the clonotype level 7 days post vaccin-
ation with 14/15 TIV in the same four individuals
vaccinated with 08/09 TIV, followed by 09 MIV and
2011-12 TIV (Fig. 1). We observed a tendency to a re-
duction in the usage frequency of IGHV1-69 and
IGHV3-7 (Fig. 5a and b). Likewise, IGHV4-39 showed a
tendency to increase (Fig. 5c).
A preferential use of certain IGHV segments and low
rates of somatic hypermutation have been described in
the primary antiviral response in mouse and in human
models [40, 41]. Thus, we assessed the overall SHM rate
in the same four individuals before and 7 days post vac-
cination with 08/09 TIV, followed by 09 MIV and 14/15
TIV. Increased SHM was observed 7 days post vaccin-
ation with 08/09 TIV (Fig. 6a). Contrastingly, SHM rates
were reduced 7 days post vaccination with 09 MIV
(Fig. 6b). Nevertheless, vaccination with 14/15 TIV
caused SHM rates to return to the pattern observed with
the 08/09 TIV (Fig. 6c). It is possible that random
sampling of lineages, particularly in those large clono-
types composed by many lineages could cause non-
independence effects that could compromise SHM
accuracy. Thus, we also estimated SHM by sampling one
lineage per randomly sampled clonotype. Consistent
with the previous strategy, SHM were reduced post vac-
cination with MIV and increased post vaccination with
08/09 TIV and 14/15 TIV (Fig. 6d-f ). Moreover, somatic
hypermutation could affect differentially according to
IGHV use, so we estimated SHM in expanded (IGHV1-69,
IGHV3-7, and IGHV4-39) or non-expanded lineages
using particular IGHV segments (IGHV1-3, IGHV3-15,
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and IGHV4-59). In the case of IGHV1-69, SHM rates
were identical to the pattern observed for the ‘bulk’ ana-
lysis. For IGHV3-7, no significant differences were found.
For IGHV4-39, an increase in SHM post-vaccination was
significant only for TIV 08/09 (Additional file 5).
Taking together the results of clonotypic and lineage
diversity, the change of IGHV use upon vaccination and
the differences in the mutation rates indicate that
immunization with the new virus induced a different
clonal response pattern than re-immunization with
seasonal variants. To prove so, a multilevel PCA was
performed to search for association patterns between
diversity, IGHV use, SHM rates, and vaccine type. We
used the day 7/day 0 ratio of clonotype and lineages
species, Dsw day 7/ Dsw day 0 ratio, the change of IGHV
clonotype frequency (Δ day 7 – day 0) and the mean
proportion (%) of all mutations, as variables for the ana-
lysis. Two components, PC1 and PC2, explained 41.2 %
and 19.8 % of the variance, respectively, with a cumula-




Fig. 4 Effect of immunization with TIV and 09 MIV on the repertoire of peripheral B-lymphocytes. The change in the relative frequency of
IGHV segment use (Δ day 7 – day 0) for TIV (red dots, n = 6) and with 09 MIV (blue dots, n = 12), for 47 IGHV segments (a), and, in detail,
for IGHV1-69 (b), for IGHV3-7 (c), and for IGHV4-39 (d). The dotted lines represent ± 2 standard deviations (±6.7) from the mean (0) (Mann–Whitney test.
***P <0.001, *P <0.05)
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Fig. 5 Longitudinal changes in IGHV segment usage upon influenza vaccination. The change in the relative VH clonotype frequency of IGHV




Fig. 6 Somatic hypermutation analysis in response to 08/09 TIV, 09 MIV, and 14/15 TIV. SHM rates (% of mutations in VH region) are shown
according to vaccination trial. In the first approach, 670 randomly sampled lineages per individual were selected and plotted (a-c). (a) 08/09 TIV;
(b) 09 MIV; and (c) 14/15 TIV. A second sampling approach was used based on selecting the single largest lineage of 250 VH clonotypes (d-f)
(Kruskal–Wallis test. Dunn’s correction for multiple testing. **P <0.01, ***P <0.001)
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two major clusters, one containing the majority of the
TIV vaccinations regardless of their pre-pandemic or
post-pandemic status, and the second cluster containing
the 09 MIV (Fig. 7). Thus, this non-supervised approach
robustly support that repeated seasonal exposures elicit
common clonal selection patterns that differ from those
elicited by an exposure to a new variant.
IGHV usage signatures associated with heterotypic
seroconversion include other segments than IGHV1-69
The observed changes in IGHV1-69 at day 7 post-08/09
TIV and 09 MIV immunization (Figs. 4b and 5a) and the
implication of this segment in broad influenza virus
strain neutralization [18] suggested that the four individ-
uals that developed heterotypic seroconversion upon 09
MIV immunization would display IGHV1-69 clonal ex-
pansions. Thus, we split the 09 MIV trial in two groups
according to their heterotypic and homotypic serocon-
version response. Only one individual (i04) with positive
heterotypic seroconversion had clonal expansion of the
IGHV1-69 (>3 standard deviations) (Fig. 8a and c). An-
other individual (i11) also had positive heterotypic sero-
conversion and an expansion in IGHV1-69, however did
not reach >3 standard deviations selection threshold.
The remaining two individuals with heterotypic serocon-
version showed individual expansions of segments
IGHV4-39 (i12) and IGHV3-33 (i13), respectively (Fig. 8a
and c). As for the individuals who did not undergo het-
erotypic seroconversion, segment IGHV1-69 was ex-
panded in two out of seven individuals (Fig. 8b and d).
Two individuals (i10 and i01) also showed expansions in
segments IGHV3-23 and IGHV4-30-2, respectively
(Fig. 8a and c, Additional file 6). The Phe60 in the CDRH2
of IGHV1-69 has been implicated in the neutralizing ac-
tivity of some anti-HA stem antibodies [18, 42]. We did
not find any correlation between the presence of Phe60
and clonal expansion nor heterosubtypic seroconversion
(Additional file 7). Taken together, these results suggest
that IGHV1-69 clonal expansions do not correlate exclu-
sively with the heterotypic response, and allowed us to
identify IGHV segments other than IGHV1-69 that may
be involved in the heterotypic seroconversion.
Another hypothesis that could be tested under our
experimental design is the original antigenic sin (OAS)
hypothesis, which states that subsequent antibody re-
sponses to new viral strains are dominated by antibodies
with higher affinity for the original immunizing variant
[43, 44]. We searched for identical VH clonotypes shared
by the same individual at day 7 post vaccination with
08/09 TIV, 09 MIV, and 14/15 TIV (n = 4 individuals;
four possible comparisons: 08/09 TIV vs. 09 MVI, 08/09
TIV vs. 14/15 TIV, 09 MVI vs. 14/15 TIV, and 08/09
Fig. 7 Principal component analysis of influenza vaccinees according to each trial. Principal Component biplot showing clustering of vaccinees
according to both TIVs or 09 MIV immunization. PCA was constructed using results of clonotype and lineage rarefaction and entropy analysis,
IGHV1-69, IGHV3-7, and IGHV4-39 use and SHM rates per individual and trial. 08/09 TIV (green), 09 MIV (red), and 14/15 TIV (blue)
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TVI vs. 09 MVI vs. 14/15 TIV). The average number of
clonotypes per individual in the three vaccination trials
was 1,894 ± 1,255. The absolute number of clonotypes
analyzed for each individual are in Additional file 3. No
shared clonotypes were found common to the three
vaccination trials in any of the individuals. Only four
clonotypes in individual i04 were shared at day 7 post
vaccination between 08/09 TIV and 09 MVI. Individual
i04 presented heterotypic seroconversion upon 09 MIV
immunization and two of the shared clonotypes used
IGHV1-69 and contributed to the IGHV1-69 clonal
expansion observed in this individual (Fig. 8b and d).
This finding is consistent with the new 2009 pdmH1N1
virus selecting B cells specific for shared epitopes with
the pre-pandemic virus. However, we found no evidence
supporting OAS.
To prove that the observed clonal expansions associ-
ated with heterotypic and homotypic seroconversion
were influenza virus-specific, we selected the largest
clone of IGHV1-69 (i04), IGHV3-33 (i13), and IGHV4-39
(i12) (heterotypic seroconvertants), and IGHV3-23 (i10,





Fig. 8 Effect of immunization with 09 MIV on the repertoire of peripheral B-lymphocytes with homo- and heterosubtypic seroconversion. Changes in
the relative frequency of use of IGHV segments (Δ day 7 – day 0) for individuals with homotypic seroconversion (n = 7) (a, c), and with heterosubtypic
seroconversion (n = 4) (b, d) for 47 IGHV segments. IGHV usage is expressed as relative transcription (unclustered reads) (a, b), and as the proportion of
clonotypes using a particular IGHV segment (c, d). The dotted line indicates three standard deviations, which corresponds to 18.5 for relative
transcription and 10.3 for clonotypic frequency above the means, 0.0014 and 0.003, respectively. Arrows indicate clonotypes selected for
experimental validation. IGHV segments in bold letters indicate relevant expansions
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the corresponding recombinant monoclonal antibody. In
the case of IGHV1-69, the clonotype shared at day 7
post immunization with 08/09 TIV and 09 MIV was se-
lected (i04.1-69_3). As no information regarding the in
vivo corresponding IgL pair, IgL genes derived of pub-
lished mAbs were used for co-transfection (Additional
file 1). The characteristics of the recombinant mAbs are
described in Fig. 9a. The IGHV1-69, IGHV3-33, and
IGHV3-23 antibodies were positive against 09 MIV by
ELISA. The i04.1-69_3 mAb (IGHV1-69) reacted with
both 08/09 TIV and 09 MIV and gave stronger signals
than the pan-influenza FI6 mAb [45]. The IGHV3-23
reacted against 08/09 TIV with higher relative affinity
than to 09 MIV (Fig. 9b and c). No reactivity against 09
MIV was found for IGHV4-39 paired with any of the
light chains tested (Fig. 9).
Discussion
Through the combination of traditional serological
analysis, high throughput sequencing applied to the
analysis of the diversity of the repertoire of B cells
and bioinformatics analysis, we have studied the
clonal response to the 2008/2009 trivalent influenza
vaccine, as well as to a subsequent vaccination with
the 2009 pdmH1N1 influenza vaccine and the 2014/
2015 trivalent influenza vaccine.
Previous work aiming at the characterization of the B
cell repertoire in response to influenza vaccination using
high-throughput sequencing revealed the power of this
approach in understanding clonal structure, mutation
patterns, the influence of age, and structural conver-
gence [46–49]. In this work, we compared in the same
four individuals, B cell clonal responses to seasonal
pre-pandemic 08/09 TIV, pandemic 09 MIV, and sea-
sonal post-pandemic 14/15 TIV applied during a 5-
year period. Since the study was initiated right at the
seasonal to pandemic transition (May, 2009), we
could be certain that the initial group of TIV vacci-
nees were naïve for the 2009 pdmH1N1 virus, provid-
ing a unique opportunity to define a B cell repertoire
baseline to a new virus, as a reference to analyze the
B cell clonal response to further re-infections (or vac-
cination) with antigenic drift variants of the pandemic
virus, as it becomes seasonal.
The comparative analysis of the serological response
to the 08/09 TIV and 09 MIV vaccines made it possible
to identify heterotypic neutralizing responses in four out
of 23 individuals vaccinated with 09 MIV, evaluated as a
four-fold increase of the neutralizing titers against a
heterologous virus (not present in 09 MIV). This is in
agreement with previous analyses of the response to
09 MIV or in individuals with a natural infection with
the 2009 pdmH1N1 virus, which demonstrated that
the response was mainly cross-reactive and cross neu-
tralizing [23, 24, 39]. The induction of heterotypic
neutralizing responses against new viruses such as the
2009 pdmH1N1 is relevant, but these are usually of
low intensity in response to vaccination with seasonal
A
B C
Fig. 9 B cell clonal expansions associated with heterotypic seroconversion are influenza-specific. (a) Structural features of recombinant monoclonal
antibodies in terms of VDJ segment use and successful VL pair. (b) Enzyme-linked immunosorbent assay of three recombinant monoclonal
antibodies derived from in silico repertoire mining of clonal expansions in segments IGHV1-69 and IGHV3-23 against TIV antigens, and
(c) against MIV antigen.
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variants [50], as was confirmed in this study (Fig. 1,
Additional file 2).
By means of the bioinformatics analysis of the se-
quences of the VH region and the application of analyt-
ical and statistical methods oriented to filter the ‘noise’
(inherent to the repertoire in individuals with a history
of exposure to different antigens), we identified consist-
ent response patterns between both TIV (pre and post-
pandemic) vaccines, that were clearly different to the
pattern elicited by 09 MIV. In order to estimate the di-
versity and heterogeneity, we applied approaches derived
from population ecology to the study of the ‘lymphoid
micro-ecosystem’ [34, 35]. Both, the pre-pandemic 2008/
09 and the post-pandemic 2014/15 vaccines induced a
reduction of the post-vaccination clonal and lineage en-
tropy with respect to its pre-immune value, which could
be explained by the numeric expansion and selection of
a reduced group of high Ig-expressing plasmablasts
(Fig. 3 and Additional file 4). Similar results were ob-
tained for the TIV by measuring the clonality index de-
rived by multiple sampling [49, 51]. An important
finding of this work, supported by the rarefaction ana-
lysis and estimates of the DSW indices, is the paradoxical
increase in the clonal and lineage diversities in the post-
vaccination repertoire induced by the 09 MIV, suggest-
ing a highly diverse clonal mobilization of B cell clones
toward the peripheral blood as consequence of the ex-
posure to the new virus, for which memory B cell re-
sponses are lacking. Interestingly, in a third vaccination
with 14/15 TIV there was no difference between pre and
post-immunization rarefaction curves (Fig. 3). Moreover,
the DSW indices in 14/15 TIV resembled that of the
08/09 TIV (Additional file 4), suggesting that the
clonal response to repeated seasonal immunizations
with TIV tends to return to the pre-pandemic pattern.
The frequency of IGHV1-69 segment use was reduced
after vaccination with TIV (Fig. 4a and b). This is
noteworthy, because this segment has been described
in heterotypic neutralizing antibodies that bind the
HA stem of various influenza subtypes, independently
of the light chain (VL) and CDRH3. This atypical rec-
ognition depends, at least partly, upon the presence
of the CDRH2 encoded Phe60 in the germ-line
IGHV1-69 segment, allowing essential hydrophobic in-
teractions with the region of the HA stem, which
takes part in the fusion of the membranes during the
infection process, and is highly conserved in various
influenza virus subtypes [10, 18, 24, 42, 52, 53].
The reduction in the use of IGHV1-69 in response to
TIV and the lack of shared IGHV1-69 clonotypes after
09 MIV vaccination (Fig. 4a and b) could imply that the
IGHV1-69 expressing B cells are displaced by clonal
competition with clonotypes directed against the immu-
nodominant epitopes of the HA globular domain.
Accordingly, we observed that TIV promoted the expan-
sion of the use of IGHV4-39, a segment involved in the
recognition of the HA globular domain and with homo-
typic neutralization capacity [23, 24] (Fig. 4a and d). Fur-
ther repertoire analysis in four individuals exposed to
two post-pandemic TIV (2012-13 and 2014-15) revealed
a trend of IGHV1-69 and IGHV4-39 usage towards the
pre-pandemic pattern. Because the globular domain of
2009 pdmH1N1 is very different from that of pre-
pandemic H1N1 strains (approximately 40 % identity),
our repertoire mining results and experimental valid-
ation with recombinant mAbs are consistent with
previous work indicating that vaccination with 09
MIV produced a positive selection of IGHV1-69+ B cells
[23, 24, 39], thus accounting for the differences in the
cross reactivity induced by the two vaccines. Alternatively,
IGHV1-69 expressing B cells deletion as the result of
08/09 TIV immunization, as in transgenic mice expressing
an anti-influenza virus BCR [4] cannot be ruled out.
The increase in the clonal frequency of IGHV3-7 was
observed in some individuals only in response to 09
MIV (Fig. 4a and c). This segment has been involved in
the homotypic neutralization of 2009 pdmH1N1 and the
1918 A(H1N1) viruses, through recognition of the
globular domain, evidencing the structural similarity be-
tween both pandemic viruses [48, 49]. Accordingly, an
increase in the clonal frequency of IGHV3-7 was ob-
served in participants with homotypic neutralization, but
not in individuals that showed heterotypic neutralization
(Figs. 4, 5, and 8).
Also noteworthy is the finding that 09 MIV was asso-
ciated with lower levels of somatic hypermutation, mea-
sured as the proportion of SHM in the VH region per
lineage. This effect contrasted with the increase of SHM
proportion 7 days post vaccination with both 2008/09
and 2014/15 TIV. Low SHM rates are characteristic of
rapid T-cell independent antiviral IgG responses in mice
[40] and humans [41]. Accordingly, the expansion of
IGHV1-69 as a result of 09 MIV immunization together
with low SHM rates may indicate an extra-follicular or
germinal center-independent IgG B cell response that
contributes to cross-reactivity in addition to a recall re-
sponse towards common antigenic determinants shared
between the pre- and the pandemic influenza strain.
Although the analysis of IGHV usage frequency re-
vealed information that it is relevant to understand
the response of the B cell repertoire to seasonal and
pandemic vaccines, the absence of correlation be-
tween the frequency of IGHV1-69 and heterotypic
seroconversion is consistent with the finding that
other IGHV segments may participate in heterotypic
neutralization. Accordingly, we identified a IGHV3-33
expansion in one individual that presented heterotypic
seroconversion (Fig. 8b and d). The IGHV3-33
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segment shares a high sequence identity to IGHV3-30
used in the pan-influenza FI6 broadly neutralizing
antibody [45]. We have demonstrated that the ob-
served clonal expansions are indeed, influenza virus
specific (although not necessarily neutralizing) and in
the case of the i04.1-69 IGHV1-69 antibody, we demon-
strated its reactivity to both 2008/09 TIV and 09 MIV.
Our results indicate that the application of vaccines
with the 2009 pdmH1N1 virus whose HA had not circu-
lated among the population for decades induced the
production of antibodies against common antigenic de-
terminants of the influenza virus that account, at least
partially, for the heterosubtypic seroconversion and pos-
sibly for the cross-reactivity against various influenza
virus subtypes. No evidence of OAS was found 7 days
post immunization with the tested vaccines, although we
cannot rule out that dominant clontoypes for the first
vaccine that could be suboptimally expanded by MIV
and TIV 14/15 were missed due to insufficient sequen-
cing depth. Moreover, the low rates of somatic hyper-
mutation as a result of 09 MIV immunization, as
compared to TIV, could indicate an ‘innate’ extra-
follicular response lead by non-antigen experienced B
cells [54] and that contributes to the cross-reactivity in-
duced by 09 MIV immunization or natural infection
with 2009 pdmH1N1.
Research on the structural complexity of the repertoire
of B cells in response to the structural complexity and
variability of influenza viruses may contribute to evaluate
experimental vaccines in terms of clonal competition,
and for the identification of those epitopes that induce
broadly neutralizing antibodies required for a universal
vaccine capable of preventing infections by a large num-
ber of virus subtypes, including new variant viruses with
pandemic potential.
Conclusion
Immunization with different influenza viral strains pro-
duce distinctive effects in terms of cross-neutralization
and the peripheral B cell repertoire, which are related
with the degree of exposures to such variants. The fac-
tors that appear to contribute to this effects are the ex-
istence of conserved epitopes within different viral
strains, however other factors such as a primary non-
germinal center differentiation pathway against the new
variants may also play a role.
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